A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Bone disorders; Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.